Company
Amicus Therapeutics
Amicus Therapeutics has 14 drugs tracked on RxWires: 4 in Phase 3, 3 in Phase 2, 1 in Phase 1/2, 5 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| migalastat hydrochloride | Phase 3 | Fabry Disease |
| SD-101-6.0 cream | Phase 3 | Epidermolysis Bullosa |
| Cipaglucosidase Alfa | Phase 3 | Pompe Disease (Late-onset) |
| AT2221 | Phase 3 | Pompe Disease (Late-onset) |
| afegostat tartrate | Phase 2 | Gaucher Disease |
| SD-101 dermal cream (3%) | Phase 2 | Epidermolysis Bullosa |
| Duvoglustat | Phase 2 | Pompe Disease |
| ATB200 | Phase 1/2 | Pompe Disease |
| AT1001 150 mg | Phase 1 | Fabry Disease |
| A (migalastat) | Phase 1 | Fabry Disease |
| GR181413A/AT1001 solution | Phase 1 | Fabry Disease |
| [14C] AT1001 | Phase 1 | Fabry Disease |
| AT2101 | Phase 1 | Type 1 Gaucher Disease |
| BNP blood sample test | Not Applicable | Hypertrophic Cardiomyopathy |
Latest
No recent events.
Follow Amicus Therapeutics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.